Robert L Van Nostrand Intra Cellular Therapies, Inc. (ITCI) insider trading activity

Robert L Van Nostrand is of Intra-Cellular Therapies, Inc.. Currently has a direct ownership of 11,340 shares of ITCI, which is worth approximately $977,167. The most recent transaction as insider was on Jun 28, 2024, when has been sold 83 shares (Common Stock) at a price of $68.49 per share, resulting in proceeds of $5,684. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 11.3K

0% 3M change

18.93% 12M change

Total Value Held $977,167

ROBERT L VAN NOSTRAND Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 28 2024	BUY Grant, award, or other acquisition	$5,684 $68.49 p/Share	83 Added 0.73%	11,340 Common Stock
Jun 23 2024	BUY Exercise of conversion of derivative security	-	1,567 Added 12.22%	11,257 Common Stock
Jun 18 2024	SELL Open market or private sale	$1,517,800 $75.89 p/Share	20,000 Reduced 67.36%	9,690 Common Stock
Jun 18 2024	BUY Exercise of conversion of derivative security	$337,200 $16.86 p/Share	20,000 Added 40.25%	29,690 Common Stock
Mar 31 2024	BUY Grant, award, or other acquisition	$5,466 $69.2 p/Share	79 Added 0.81%	9,690 Common Stock
Feb 27 2024	SELL Open market or private sale	$1,458,400 $72.92 p/Share	20,000 Reduced 67.54%	9,611 Common Stock
Feb 27 2024	BUY Exercise of conversion of derivative security	$371,200 $18.56 p/Share	20,000 Added 40.31%	29,611 Common Stock
Dec 31 2023	BUY Grant, award, or other acquisition	$5,443 $71.62 p/Share	76 Added 0.78%	9,611 Common Stock
Sep 30 2023	BUY Grant, award, or other acquisition	$5,469 $52.09 p/Share	105 Added 1.09%	9,535 Common Stock
Jun 30 2023	BUY Grant, award, or other acquisition	$5,382 $63.32 p/Share	85 Added 0.89%	9,430 Common Stock
Apr 17 2023	SELL Open market or private sale	$630,000 $63.0 p/Share	10,000 Reduced 51.69%	9,345 Common Stock
Apr 17 2023	BUY Exercise of conversion of derivative security	$130,500 $13.05 p/Share	10,000 Added 34.08%	19,345 Common Stock
Mar 31 2023	BUY Grant, award, or other acquisition	$5,144 $54.15 p/Share	95 Added 1.01%	9,345 Common Stock
Dec 30 2022	BUY Grant, award, or other acquisition	$5,133 $52.92 p/Share	97 Added 1.04%	9,250 Common Stock
Sep 30 2022	BUY Grant, award, or other acquisition	$5,118 $46.53 p/Share	110 Added 1.19%	9,153 Common Stock
Aug 11 2022	SELL Open market or private sale	$1,709,400 $56.98 p/Share	30,000 Reduced 76.84%	9,043 Common Stock
Aug 11 2022	BUY Exercise of conversion of derivative security	$382,500 $12.75 p/Share	30,000 Added 43.45%	39,043 Common Stock
Jun 30 2022	BUY Grant, award, or other acquisition	$6,165 $57.08 p/Share	108 Added 1.18%	9,043 Common Stock
Mar 31 2022	BUY Grant, award, or other acquisition	$7,710 $61.19 p/Share	126 Added 1.39%	8,935 Common Stock
Dec 31 2021	BUY Grant, award, or other acquisition	$7,746 $52.34 p/Share	148 Added 1.65%	8,809 Common Stock
Sep 30 2021	BUY Grant, award, or other acquisition	$8,015 $37.28 p/Share	215 Added 2.42%	8,661 Common Stock
Jun 30 2021	BUY Grant, award, or other acquisition	$7,062 $40.82 p/Share	173 Added 2.01%	8,446 Common Stock
Mar 31 2021	BUY Grant, award, or other acquisition	$7,057 $33.93 p/Share	208 Added 2.45%	8,273 Common Stock
Dec 31 2020	BUY Grant, award, or other acquisition	$7,060 $31.8 p/Share	222 Added 2.68%	8,065 Common Stock
Sep 30 2020	BUY Grant, award, or other acquisition	$7,082 $25.66 p/Share	276 Added 3.4%	7,843 Common Stock

Also insider at

YTEN

YIELD10 BIOSCIENCE, INC. Basic Materials

Director

SLS

SELLAS Life Sciences Group, Inc. Healthcare

Director

RLV